50% 16,341,669 C.0009 Is it making a come back?

New Post Public Reply Private Reply Replies (1) Message Board
znewcar1
646
50% 16,341,669 C.0009 Is it making a come back?

NEXT DYNAMICS INC. (NEXD) Stock Research Links

NEXD Board Company Profile Buy Rating Time & Sales News Filings Financials
The majority of my post are the top 20% gainer! To decode them its (ticker ID, % Changed, Volume, Close price and Float) I typically put V,C&F as a prefix to that number and use K, M and B as a suffix (Kilo, Million & Billion) for volume and float. I may also use S for Support and R for Resistance.

I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

AST SpaceMobile: Analyzing Growth Amid Market Fluctuations

Updated Category News Views 151

Market Movement and AST SpaceMobile's Growth Potential AST SpaceMobile Inc (NASDAQ: ASTS) has recently experienced a period of consolidation following a remarkable rally that saw its stock increase by triple digits in under three months. For investors monitoring the daily fluctuations in AST SpaceMobile’s stock chart, this pullback may trigger concerns. However, the...

Continue Reading
Foghorn Therapeutics: Future Directions and Financial Health

Updated Category News Views 92

Foghorn Therapeutics: Future Directions and Financial Health Foghorn Therapeutics Inc. (NASDAQ: FHTX) is embarking on an exciting journey in the field of oncology, focusing on groundbreaking therapies that seamlessly integrate with the body’s chromatin regulatory mechanisms. Among these is FHD-909, a pioneering oral selective SMARCA2 inhibitor. This focus highlights the...

Continue Reading
Essen Health Achieves Top Savings Rate in 2024

Updated Category News Views 11

Leading the Pack with Impressive Savings When it comes to healthcare innovation and cost efficiency, Essen Health Care's Atlas IPA is firing on all cylinders. In the cutthroat world of healthcare savings, where every penny counts, they’ve managed to crank out a 21% net savings rate. This isn’t just a small-town record, folks. We're talking about leading the nation...

Continue Reading
Alps Group Completes Merger with Globalink Investment and Expands

Updated Category News Views 242

Alps Group's Landmark Merger with Globalink Investment Inc. Alps Group Inc, the parent company of Alps Life Sciences Inc., recently celebrated the closing of its business combination with Globalink Investment Inc. This merger marks a significant milestone in the biotechnology landscape, showcasing Alps Group's commitment to advancing healthcare solutions. The Journey to...

Continue Reading
Morien Resources Secures Funding for Future Development Goals

Updated Category News Views 75

Morien Resources Corp. Secures Financing Morien Resources Corp. is thrilled to announce the successful closing of a significant non-brokered Listed Issuer Financing Exemption offering, known as the LIFE Offering. The company has raised gross proceeds of $1,600,000, allowing it to issue 8,888,889 common shares at a price of $0.18 each. This injection of capital is pivotal...

Continue Reading